CJ BioscienceCJ 바이오사이언스
311690 · KOSDAQ · ₩311690 · CJ 바이오사이언스
₩3,690▲ ₩40 (1.10%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 21.4% | 18.9% | 10.5% | 33.1% | 34.5% | 37.9% |
| Operating margin | −624.9% | −671.2% | −987.8% | −575.0% | −815.6% | −231.7% |
| Net margin | −607.2% | −650.1% | −947.3% | −411.0% | −856.8% | −441.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −0.4% | +6.5% | −37.8% | +36.8% | −6.6% | — |
| Operating income growth | +7.3% | +27.6% | −6.8% | +3.5% | −228.8% | — |
| Net income growth | +7.0% | +26.9% | −43.3% | +34.4% | −81.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −46.8% | −36.5% | −44.0% | −37.8% | −50.8% | −21.9% |
| Return on assets | −35.2% | −27.9% | −34.4% | −25.1% | −33.6% | −16.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 44.7% | 34.9% | 28.1% | 27.5% | 84.0% | 32.4% |
| Net debt to equity | −77.1% | −81.8% | −88.7% | −84.1% | −51.8% | −49.6% |
| Current ratio | 288.2% | 360.5% | 414.4% | 442.9% | 145.6% | 342.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: CJ Bioscience / CJ 바이오사이언스 / 311690 / KRX:311690
Source: KRX statistical information